Evidence map›Paper›PMID 28533226›Full record

Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2017

IGF1R Protein Expression Is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2

Monica M Reinholz, Beiyun Chen, Amylou C Dueck, Kathleen Tenner, Karla Ballman, Darren Riehle, Robert B Jenkins, Xochiquetzal J Geiger, Ann E McCullough, Edith A Perez

Open access · bronzeAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Monica M ReinholzDivision of Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
Beiyun ChenDivision of Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
Amylou C DueckSection of Biostatistics, Mayo Clinic, Scottsdale, Arizona.
Kathleen TennerDivision of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota.
Karla BallmanDivision of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota.
Darren RiehleDivision of Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
Robert B JenkinsDivision of Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
Xochiquetzal J GeigerDivision of Anatomic Pathology, Mayo Clinic, Jacksonville, Florida.
Ann E McCulloughDivision of Pathology, Mayo Clinic, Scottsdale, Arizona.
Edith A PerezDivision of Hematology and Oncology, Mayo Clinic, Jacksonville, Florida. perez.edith@gene.com.
Mayo Clinic · USJacksonville College · USMayo Clinic in Arizona · US

Funding

Member Site CoreU10CA180821 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Evanthia Galanis · 2014 to 2026
$177.3M
TRANSLATIONAL RESEARCHU10CA025224 · NCI · MAYO CLINIC ROCHESTER · PI BUCKNER, JAN C · 1985 to 2013
$85.0M
THE ALLIANCE NCTN BIOREPOSITORY AND BIOSPECIMEN RESOURCEU24CA196171 · NCI · WASHINGTON UNIVERSITY · PI Mine Cicek, Wendy Frankel · 2015 to 2026
$35.0M
North Central Cancer Treatment Group (NCCTG) Biospecimen ResourceU24CA114740 · NCI · MAYO CLINIC ROCHESTER · PI BUCKNER, JAN C · 2005 to 2014
$8.6M
Predictive Biomarkers of Adjuvant Trastuzumab in the HER2+N9831 Intergroup TrialR01CA129949 · NCI · MAYO CLINIC JACKSONVILLE · PI PEREZ, EDITH A. · 2008 to 2011
$1.3M
NCI NIH HHS R01 CA129949NCI NIH HHS U10 CA025224NCI NIH HHS U10 CA180821NCI NIH HHS U24 CA114740NCI NIH HHS U24 CA196171
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultAgedBreast NeoplasmsDisease-Free SurvivalDrug Resistance, NeoplasmErb-b2 Receptor Tyrosine KinasesFemaleGene Expression Regulation, NeoplasticHumansMiddle AgedNeoplasm StagingReceptor, IGF Type 1Receptors, EstrogenReceptors, ProgesteroneReceptors, SomatomedinTrastuzumabERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesIGF1R protein, humanReceptor, IGF Type 1Receptors, EstrogenReceptors, ProgesteroneReceptors, SomatomedinTrastuzumab

Identifiers

PMID28533226
PMCPMC5769872
OpenAlexW2618728579

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.